{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34.7","upperLimit":"70.9","value":"53.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with a confirmed best response of CR, CRh, PR, or CI by mIWG-MRT-ECNM criteria. The mIWG-MRT-ECNM criteria were based on findings from bone marrow biopsy and aspirate, and peripheral blood smear; bone marrow cytogenetics; other extracutaneous tissue biopsies (when available); liver and spleen imaging; and other clinical and laboratory parameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.","id":"OG000","title":"Avapritinib"}],"paramType":"NUMBER","populationDescription":"Response-evaluable Population: all participants who received ≥1 dose of avapritinib, were deemed evaluable per mIWG-MRT-ECNM criteria at baseline as assessed by local investigator and had 1 of the following conditions: ≥2 complete postbaseline bone marrow assessments and had been on study for ≥6 cycles; had an end of study visit. Here, 'Overall Number of Participants Analyzed' signifies those participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline through Month 19","title":"ORR Based on mIWG-MRT-ECNM Response Criteria as Assessed by Local Investigator","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}